EUVIMEDEUVIMED entdecken
Open Access

Insulin-like growth factor binding protein-2 in at-risk adults and autopsy-confirmed Alzheimer brains

Marc James Quesnel iD, Anne Labonté iD, Cynthia Picard iD, Henrik Zetterberg iD, Kaj Blennow iD, Ann Brinkmalm iD, Sylvia Villeneuve iD, Judes Poirier iD, Alzheimer’s Disease Neuroimaging Initiative, PREVENT-AD Research Group

Brain · 2024

DOI: 10.1093/brain/awad398 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Brain, 2024. Verfasst von Marc James Quesnel und 9 weiteren Autor:innen. Beteiligte Einrichtung: McGill University, Montréal, QC H3A 1A1, Canada. Hauptthemen laut MEDLINE: Alzheimer Disease, Insulin-Like Growth Factor Binding Protein 2, Amyloid beta-Peptides, tau Proteins. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 94 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIA NIH HHS, Alzheimer's Association, CIHR.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Insulin, insulin-like growth factors (IGF) and their receptors are highly expressed in the adult hippocampus. Thus, disturbances in the insulin-IGF signalling pathway may account for the selective vulnerability of the hippocampus to nascent Alzheimer's disease (AD) pathology. In the present study, we examined the predominant IGF-binding protein in the CSF, IGFBP2. CSF was collected from 109 asymptomatic members of the parental history-positive PREVENT-AD cohort. CSF levels of IGFBP2, core AD and synaptic biomarkers were measured using proximity extension assay, ELISA and mass spectrometry. Cortical amyloid-beta (Aβ) and tau deposition were examined using 18F-NAV4694 and flortaucipir. Cognitive assessments were performed during up to 8 years of follow-up, using the Repeatable Battery for the Assessment of Neuropsychological Status. T1-weighted structural MRI scans were acquired, and neuroimaging analyses were performed on pre-specified temporal and parietal brain regions. Next, in an independent cohort, we allocated 241 dementia-free ADNI-1 participants into four stages of AD progression based on the biomarkers CSF Aβ42 and total-tau (t-tau). In this analysis, differences in CSF and plasma IGFBP2 levels were examined across the pathological stages. Finally, IGFBP2 mRNA and protein levels were examined in the frontal cortex of 55 autopsy-confirmed AD and 31 control brains from the Quebec Founder Population (QFP) cohort, a unique population isolated from Eastern Canada. CSF IGFBP2 progressively increased over 5 years in asymptomatic PREVENT-AD participants. Baseline CSF IGFBP2 was positively correlated with CSF AD biomarkers and synaptic biomarkers, and negatively correlated with longitudinal changes in delayed memory (P = 0.024) and visuospatial abilities (P = 0.019). CSF IGFBP2 was negatively correlated at a trend-level with entorhinal cortex volume (P = 0.082) and cortical thickness in the piriform (P = 0.039), inferior temporal (P = 0.008), middle temporal (P = 0.014) and precuneus (P = 0.033) regions. In ADNI-1, CSF (P = 0.009) and plasma (P = 0.001) IGFBP2 were significantly elevated in Stage 2 [CSF Aβ(+)/t-tau(+)]. In survival analyses in ADNI-1, elevated plasma IGFBP2 was associated with a greater rate of AD conversion (hazard ratio = 1.62, P = 0.021). In the QFP cohort, IGFBP2 mRNA was reduced (P = 0.049); however, IGFBP2 protein levels did not differ in the frontal cortex of autopsy-confirmed AD brains (P = 0.462). Nascent AD pathology may induce an upregulation in IGFBP2 in asymptomatic individuals. CSF and plasma IGFBP2 may be valuable markers for identifying CSF Aβ(+)/t-tau(+) individuals and those with a greater risk of AD conversion.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Alzheimer DiseaseInsulin-Like Growth Factor Binding Protein 2Amyloid beta-Peptidestau ProteinsBiomarkersBrainHumansFemaleMaleAgedMiddle AgedAutopsyAged, 80 and overDisease ProgressionCohort StudiesMagnetic Resonance ImagingNeuropsychological Tests

Stichwörter der Autor:innen

Alzheimer's diseaseRBANScerebrospinal fluidinsulin-like growth factorinsulin-like growth factor-binding protein-2post-mortem brain tissue

Substanzen

Insulin-Like Growth Factor Binding Protein 2Amyloid beta-PeptidesIGFBP2 protein, humantau ProteinsBiomarkers

Autor:innen und Institutionen

  • McGill University, Montréal, QC H3A 1A1, Canada.
  • Douglas Mental Health University Institute, Montréal, QC H4H 1R3, Canada.
  • Centre for the Studies in the Prevention of Alzheimer's Disease, Douglas Mental Health University Institute, Montréal, QC H4H 1R3, Canada.
  • Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy, University of Gothenburg, Gothenburg 413 45, Sweden.
  • Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal 431 80, Sweden.
  • Department of Neurodegenerative Disease, UCL Institute of Neurology, London WC1N 3BG, UK.

ORCID-Profile: Marc James Quesnel, Anne Labonté, Cynthia Picard, Henrik Zetterberg, Kaj Blennow, Ann Brinkmalm, Sylvia Villeneuve, Judes Poirier

Förderung

  • NIA NIH HHS
  • Alzheimer's Association
  • CIHR
  • Fonds de recherche du Québec-Santé
  • Canadian Institutes of Health Research
  • JL Levesque Foundation.
  • McGill University
  • Wallenberg Scholar

Zitieren

APA

Quesnel, M. J., Labonté, A., Picard, C., Zetterberg, H., Blennow, K., Brinkmalm, A., Villeneuve, S., Poirier, J., Alzheimer’s Disease Neuroimaging Initiative, & PREVENT-AD Research Group (2024). Insulin-like growth factor binding protein-2 in at-risk adults and autopsy-confirmed Alzheimer brains. Brain. https://doi.org/10.1093/brain/awad398

Vancouver

Quesnel MJ, Labonté A, Picard C, Zetterberg H, Blennow K, Brinkmalm A, et al. Insulin-like growth factor binding protein-2 in at-risk adults and autopsy-confirmed Alzheimer brains. Brain. 2024. doi:10.1093/brain/awad398

BibTeX
@article{Quesnel2024,
  author = {Quesnel, Marc James and Labonté, Anne and Picard, Cynthia and Zetterberg, Henrik and Blennow, Kaj and Brinkmalm, Ann and Villeneuve, Sylvia and Poirier, Judes and Alzheimer’s Disease Neuroimaging Initiative, Alzheimer’s Disease Neuroimaging Initiative and PREVENT-AD Research Group, PREVENT-AD Research Group},
  title = {Insulin-like growth factor binding protein-2 in at-risk adults and autopsy-confirmed Alzheimer brains},
  journal = {Brain},
  year = {2024},
  doi = {10.1093/brain/awad398}
}
Kostenlos starten →